Close
Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

BIO Congratulates Senate on Passage of GMO Disclosure Package

BIO applauds and commends the U.S. Senate for approving the bipartisan Roberts-Stabenow GMO labeling and disclosure solution.

BIO Applauds Senate Support of GMO Disclosure Package

Food and ag groups urge Senate passage this week Washington, D.C. (July 7, 2016) – The Biotechnology Innovation Organization (BIO) joins more than a thousand food and agriculture organizations from across the country in applauding action in the U.S. Senate to advance the bipartisan Roberts-Stabenow GMO labeling and disclosure solution.

BIO Response to Hillary Clinton’s Initiative on Technology & Innovation

BIO welcomes many of the broad proposals put forth in Secretary Clinton’s Tech & Innovation Agenda and we share her optimism in the power of American innovation and ingenuity to address global health, environmental and food-supply challenges.

BIO Thanks Senators for Supporting Higher RFS Volumes

Today, a bipartisan group of 39 Senators -- led by Sens. Charles Grassley (R-IA), Amy Klobuchar (D-MN) -- urged EPA to get the Renewable Fuel Standard (RFS) “back on track by setting blending targets where Congress intended and by removing the distribution waiver.”

BIO Welcomes Senate Agreement on GMO Labeling

Congress urged to “act immediately” to enact national program Washington, D.C. (June 23, 2016) – Senate leaders announced today an agreement on legislative language aimed at establishing national standards for GMO food labeling and disclosure.  

BIO Strongly Opposes H.R. 5573

Bill would undermine critical work of biotechnology companies developing new cures and treatments. BIO SVP for Federal Government Relations released the following statement regarding H.R. 5573 and companion legislation in the Senate, which would amend the Public Health Service Act to shorten the exclusivity period for innovative biological products from 12 to 7 years.

Combination Products: BIO Comments on FDA Draft Guidance Human Factors Studies and Related Clinical Considerations in Combination Product Design and Development”

Re: Docket No. FDA-2015-D-4848: Human Factors Studies and Related Clinical Considerations in Combination Product Design and Development ...

Biosimilars: BIO Comments on FDA Draft Guidance Labeling for Biosimilar Products

Re: Draft Guidance for Industry: Labeling for Biosimilar Products (Docket No. FDA-2016-D-0643 (April 4, 2016)) ...

CMC: BIO Submits Comments on FDA Draft Guidance Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information

Re: Docket No. FDA-2016-D-0973: Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information

...

BIO Statement on House GOP Health Care Plan

Plan contains a number of promising proposals to protect patient access, foster medical innovation. Biotechnology Innovation Organization (BIO) President for Advocacy, Law and Public Policy Tom DiLenge released the following statement regarding the House GOP health plan released today: Speaker Ryan and his colleagues in the House are to be commended for their leadership and willingness to solve some of the most challenging problems facing our nation’s health care system. While we are still reviewing today’s detailed plan, we were encouraged by a number of specific proposals."